PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by KBC Group NV

KBC Group NV increased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 36.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,045 shares of the biopharmaceutical company’s stock after acquiring an additional 813 shares during the period. KBC Group NV’s holdings in PTC Therapeutics were worth $137,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PTCT. CWM LLC grew its stake in shares of PTC Therapeutics by 354.7% during the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 2,096 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in PTC Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 492 shares in the last quarter. Janney Montgomery Scott LLC grew its position in PTC Therapeutics by 8.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 455 shares during the period. Creative Planning increased its holdings in PTC Therapeutics by 19.0% in the second quarter. Creative Planning now owns 10,128 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 1,619 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of PTC Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,795 shares of the biopharmaceutical company’s stock valued at $549,000 after acquiring an additional 5,783 shares during the period.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, CAO Christine Marie Utter sold 1,291 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total value of $58,533.94. Following the transaction, the chief accounting officer now directly owns 65,983 shares of the company’s stock, valued at $2,991,669.22. This represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric Pauwels sold 1,599 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total transaction of $72,498.66. Following the transaction, the chief executive officer now owns 88,941 shares in the company, valued at $4,032,584.94. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,737 shares of company stock valued at $10,920,687. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on PTCT. Morgan Stanley raised PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $45.00 to $67.00 in a research note on Friday, December 13th. Cantor Fitzgerald raised their price target on PTC Therapeutics from $76.00 to $113.00 and gave the company an “overweight” rating in a research report on Monday. The Goldman Sachs Group lifted their price target on PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a research note on Wednesday, December 4th. Citigroup increased their price objective on shares of PTC Therapeutics from $26.00 to $32.00 and gave the company a “sell” rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. lifted their target price on shares of PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $57.85.

PTC Therapeutics Trading Down 0.4 %

Shares of PTCT stock opened at $49.79 on Friday. The firm has a fifty day simple moving average of $46.23 and a 200-day simple moving average of $40.12. The company has a market capitalization of $3.84 billion, a PE ratio of -8.38 and a beta of 0.62. PTC Therapeutics, Inc. has a twelve month low of $23.58 and a twelve month high of $54.16.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.15. The firm had revenue of $196.79 million for the quarter, compared to the consensus estimate of $173.51 million. During the same quarter last year, the business earned ($1.76) earnings per share. Equities research analysts predict that PTC Therapeutics, Inc. will post -4.56 EPS for the current year.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.